FDA Widens Talzenna Label After 52% Cut in Progression or Death Risk

The US Food and Drug Administration has expanded the approval of Pfizer's Talzenna (talazoparib) taken with Xtandi (enzalutamide). The pair can now be used earlier in metastatic prostate cancer, for men whose tumours carry homologous recombination repair (HRR) gene mutations. Pfizer announced the decision on Oct. 26, 2026.

What happened

The new label covers metastatic prostate cancer that is still sensitive to hormone therapy, which the FDA calls androgen pathway modulation-naive or -sensitive disease. Patients must have an HRR mutation found by an FDA-authorized test. Both BRCA and non-BRCA mutations are included, Pfizer said.

Until now, the combination was approved in the US only for castration-resistant disease, a later stage. That first approval came in 2023. The FDA reviewed the new application under priority review.

The decision rests on the phase 3 TALAPRO-3 trial, which enrolled 599 patients. Sites were in the US, Canada, Europe, South America and the Asia-Pacific region. Patients got Talzenna or a placebo, each on top of Xtandi.

• Main result: the combination lowered the risk of radiographic progression or death by an estimated 52% compared with placebo plus Xtandi, Pfizer said (hazard ratio 0.48).
• Time without progression: the median was not reached in the Talzenna group, against 45.8 months in the placebo group, CancerNetwork reported.
• Three years: Pfizer estimated that 77% of patients on the combination were still free of progression.
• Survival: an interim analysis showed a trend toward longer overall survival, a key secondary goal, CancerNetwork reported.

Anemia was the main side effect. Grade 3 or higher anemia occurred in 51% of patients on the combination and 3% in the control group, Pfizer said. Five percent stopped Talzenna because of it.

Why it matters

About 25% of men with this hormone-sensitive form of the disease have HRR mutations, according to Pfizer. The new label lets them get the targeted combination before their cancer becomes castration-resistant. Pfizer said the benefit was consistent across BRCA and non-BRCA groups.

The approval also puts weight on genetic testing at diagnosis, since only patients with a confirmed mutation qualify. Pharmaceutical Technology noted that the shift reflects a wider move toward mutation-specific cancer drugs.

What it means for people in the industry

Pfizer and Astellas jointly develop and sell Xtandi in the US, Pfizer said. Eligibility depends on an FDA-authorized HRR test. CURE noted that the FDA had already approved FoundationOne CDx, a tissue test, and FoundationOne Liquid CDx, a blood test. The trial's global lead investigator said the approval reinforces the importance of biomarker testing at diagnosis, in Pfizer's release.

Pfizer said a filing is under review at the European Medicines Agency, with other global filings planned or underway. The sources do not mention a Health Canada decision. That is one to watch for Canadian patients and teams.

This article is news, not medical advice.

See open pharma jobs in the US and Canada

Sources

• Pfizer’s Talzenna Plus Xtandi FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting, Pfizer release via Drugs.com
• FDA Approves Talazoparib/Enzalutamide for HRR Gene-Altered Metastatic Prostate Cancer, CancerNetwork
• FDA Approves Talzenna Plus Xtandi in Hormone-Sensitive Prostate Cancer, CURE
• Pfizer’s prostate cancer combo moves to earlier line on expanded US approval, Pharmaceutical Technology